UBS Group’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,815
| Closed | -$1.27K | – | 10292 |
|
|
2023
Q1 | $1.27K | Buy |
+1,815
| New | +$1.67K | ﹤0.01% | 8770 |
|
|
2022
Q4 | – | Sell |
-27
| Closed | – | – | 11496 |
|
|
2022
Q3 | $0 | Sell |
27
-17,567
| -100% | -$100K | ﹤0.01% | 11394 |
|
|
2022
Q2 | $73K | Buy |
17,594
+15,127
| +613% | +$53.3K | ﹤0.01% | 5658 |
|
|
2022
Q1 | $9K | Buy |
2,467
+2,442
| +9,768% | +$11K | ﹤0.01% | 8604 |
|
|
2021
Q4 | $0 | Buy |
+25
| New | +$127 | ﹤0.01% | 11016 |
|
|
2021
Q3 | – | Sell |
-3,005
| Closed | -$21K | – | 10383 |
|
|
2021
Q2 | $21K | Buy |
3,005
+1,286
| +75% | +$6.93K | ﹤0.01% | 7293 |
|
|
2021
Q1 | $10K | Buy |
1,719
+404
| +31% | +$2.45K | ﹤0.01% | 7953 |
|
|
2020
Q4 | $6K | Buy |
1,315
+367
| +39% | +$1.58K | ﹤0.01% | 7796 |
|
|
2020
Q3 | $4K | Sell |
948
-485
| -34% | -$9.7K | ﹤0.01% | 7466 |
|
|
2020
Q2 | $41K | Buy |
1,433
+1,153
| +412% | +$26.7K | ﹤0.01% | 6046 |
|
|
2020
Q1 | $6K | Sell |
280
-5,449
| -95% | -$124K | ﹤0.01% | 7254 |
|
|
2019
Q4 | $113K | Buy |
5,729
+5,176
| +936% | +$73.6K | ﹤0.01% | 5941 |
|
|
2019
Q3 | $8K | Buy |
+553
| New | +$8.58K | ﹤0.01% | 7301 |
|
UBS Group's STSA Position: Q2 2023 in Review
UBS Group sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 1,815 shares — an estimated $1.27K sold.
UBS Group first reported a position in STSA in Q3 2019 and held it in 13 quarters. The position peaked at $113K in Q4 2019. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- UBS Group reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 1,815 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $1.27K.
- UBS Group first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 13 quarters.
- UBS Group's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $113K in Q4 2019.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.